Actualités de Ingelheim

21.09.2015 – 10:00
BioMed X GmbH
Boehringer Ingelheim and BioMed X apply crowdsourcing to establish a team of scientists for identifying key epigenetic regulators of COPD
Ingelheim and Heidelberg (ots) - - Aims to identify of novel epigenetic drivers to find new approaches for treating COPD - Crowdsourcing used to find unconventional solutions and identify the best talent from around the world - New research team will be established at the BioMed X Innovation Center in Heidelberg, ...
plus
27.09.2014 – 09:01
Boehringer Ingelheim
Boehringer Ingelheim's afatinib Achieves Primary Endpoint in Global Phase III Study in Recurrent/Metastatic Head and Neck Squamous Cell Cancer
Ingelheim, Germany (ots/PRNewswire) - - Results from the LUX-Head & Neck 1 study show afatinib* significantly delayed tumour growth versus chemotherapy in patients following failure of their previous treatment, reducing the risk for disease progression by 20% - Head and neck cancer has a very poor prognosis with no ...
plus